Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRC

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Al-Hajeili
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Al-Hajeili1, M. Serzan2, P. Prins3, J. Marshall4
  • 1Georgtown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA, /
  • 2Georgetown University Hospital, Washington, District of Columbia, USA, /
  • 3Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University, Washington, District of Columbia, USA, /
  • 4Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA, /

Abstract

The concept of maintenance therapy in metastatic colorectal cancer (mCRC) after induction/adjuvant therapy is well established based on improvement in progression free survival (PFS) and the trend toward improvement in overall survival (OS). Surgery remains the only curative option although the failure rate is high. For mCRC patients who undergo surgical resection of their metastatic lesions, chemotherapy agents are used in different forms; neo-adjuvant therapy, conversion therapy or adjuvant therapy. Beyond this approach, there is no established strategy other than surveillance for mCRC patients who underwent surgical resection and achieved no evidence of disease (NED). These patients have radiographic NED but they may still harbor sub-radiographic metastasis, hence is the argument for maintenance therapy to keep the sub-radiographic metastasis under continuous suppression. In this study we assess the benefit of maintenance therapy in mCRC patients who underwent surgery and achieved NED.